In conclusion, our study demonstrates that TM4SF19 deletion in macrophages protects mice from obesity-induced metabolic dysfunction and suggests that TM4SF19-mediated control of lysosomal activity is a potential therapeutic target to facilitate the resolution of obesity-induced adipose tissue inflammation and related disorders. This evidence concerns the gene TM4SF19 and obesity due to melanocortin 4 receptor deficiency.